Products

Mailboard

Email inspiration & research for high performing teams

mailboard.com Data & Analytics / Market & Competitive Intelligence

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
Freemium model, plan pricing not identified yet
Creators
Dimitris
No social account linked
Launched
2y ago
2024-08-08 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions

  • Launched on BetaListLaunch

    Mailboard – Find, save, and analyze the internet's best emails. — Find, save, and analyze the internet's best emails.

    Aug 8, 2024 · 2y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct41%
  • Organic Search32%
  • Referrals11%
  • Social6%
  • Other10%

Countries

  • Canada85%
  • Colombia15%

Search

Domain authority —Domain registered 2001-09-05

KeywordMonthly volume
mailboard550
mailbpard130

Traffic data: Vaneform

Pricing

Free
Unknown

Trial: None · Observed 2026-11-05 · Pricing page

Pages & changes

Tracked since 2026-08-12

Key pages

Weekly snapshots
mailboard.com/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does Mailboard cost?
Free: Unknown. Observed 2026-11-05. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Mailboard get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Mailboard and what platforms does it support?
Mailboard is catalogued under Market & Competitive Intelligence: Email inspiration & research for high performing teams. Supported platforms: Web.

Related products in this category

Data & Analytics / Market & Competitive Intelligence

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.